Table 1.
Patient characteristicsa
| Early breast cancer | Metastatic breast cancer |
|---|---|
| Number of patients enrolled = 25 | Number of patients enrolled = 25 |
| Age, years | Age, years |
| Median (range), 59 (26 to 76) | Median (range), 59 (36 to 83) |
| ECOG performance status, n (%) | ECOG performance status, n (%) |
| 0 24 (96%) | 0 8 (32%) |
| 1 1 (4%) | 1 13 (52%) |
| 2 0 (0%) | 2 4 (16%) |
| Histology, n (%) | Histology, n (%) |
| Ductal 22 (88%) | Ductal 20 (80%) |
| Lobular 3 (12%) | Lobular 1 (4%) |
| Other 0 (0%) | Unknown 4 (16%) |
| Menopausal status, n (%) | Menopausal status, n (%) |
| Premenopausal 8 (32%) | Premenopausal 4 (16%) |
| Perimenopausal 1 (4%) | Perimenopausal 1 (4) |
| Postmenopausal 16 (64%) | Postmenopausal 20 (80%) |
| Hormone receptor status, n (%) | Hormone receptor status, n (%) |
| ER-positive/PR-positive 11 (44%) | ER-positive/PR-positive 11 (44%) |
| ER-positive/PR-negative 6 (24%) | ER-positive/PR-negative 3 (12%) |
| ER-negative/PR-positive 1 (4%) | ER-negative/PR-positive 2 (8%) |
| ER-negative/PR-negative 7 (28%) | ER-negative/PR-negative 9 (36%) |
| Tumour size, n (%) | Number of disease sites, n (%) |
| 1 to 1.9 cm (T1) 6 (24%) | 1 7 (28%) |
| 2 to 5 cm (T2) 16 (64%) | 2 9 (36%) |
| >5 cm (T3) 1 (4%) | 3 4 (16%) |
| Unknown 2 (8%) | ≥4 5 (20%) |
| Tumour grade, n (%) | Line of treatment, n (%) |
| I 2 (8%) | First 11 (44%) |
| II 9 (36%) | Second 7 (28%) |
| III 13 (52%) | ≥Third 7 (28%) |
| Unknown 1 (4%) | |
| Primary breast cancer at presentation, n (%) | |
| Early 9 (36%) | |
| Positive nodes, n (%) | Metastatic 16 (64%) |
| 0 (N0) 11 (44%) | |
| 1 to 3 (N1) 9 (36%) | Visceral disease, n (%) |
| 4 to 9 (N2) 2 (8%) | Yes 13 (52%) |
| ≥10 (N3) 2 (8%) | No 12 (48%) |
aECOG = Eastern Cooperative Oncology Group; ER = oestrogen receptor; PR = progesterone receptor.